• 1
    Demicheli V, Jefferson T, Rivetti D, Deeks J. Prevention and early treatment of influenza in healthy adults. Vaccine 2000; 18:9571030.
  • 2
    Jefferson T, Rivetti D, Rivetti A, Rudin M, Di Pietrantonj C, Demicheli V. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. Lancet 2005; 366:11651174.
  • 3
    Clements ML, Betts RF, Tierney EL, Murphy BR. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild type virus. J Clin Microbiol 1986; 24:157160.
  • 4
    Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med 2005; 11:4553.
  • 5
    Doherty PC, Topham DJ, Tripp RA, Cardin RD, Brooks JW, Stevenson PG. Effector CD4+ and CD8+ T-cell mechanisms in the control of respiratory virus infections. Immunol Rev 1997; 159:105117.
  • 6
    Briscoe JH. Intranasal immunization with inactivated influenza virus vaccine in a boys' boarding school. Practitioner 1975; 214:821826.
  • 7
    Davis SS. Nasal vaccines. Adv Drug Deliv Rev 2001; 51:2142.
  • 8
    Mutsch M, Zhou W, Rhodes P et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med 2004; 350:896903.
  • 9
    Mizuno D, Kimoto T, Takei T et al. Surfactant protein C is an essential constituent for mucosal adjuvanticity of Surfacten, acting as an antigen delivery vehicle and inducing both local and systemic immunity. Vaccine 2011; 29:53685378.
  • 10
    Belshe RB, Nichol KL, Black SB et al. Safety, efficacy, and effectiveness of live, attenuated, cold-adapted influenza vaccine in an indicated population age 5–49 years. Clin Infect Dis 2004; 39:920927.
  • 11
    Belshe RB, Edwards KM, Vesikari T et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007; 356:685696.
  • 12
    Esposito S, Montinaro V, Groppali E, Tenconi R, Semino M, Principi N. Live attenuated intranasal influenza vaccine. Hum Vaccin Immunother 2012; 8:1720.
  • 13
    Konishi M, Chida S, Shimada S et al. Surfactant replacement therapy in premature babies with respiratory distress syndrome: factors affecting the response to surfactant and comparison of outcome from 1982–86 and 1987–91. Acta Paediatr Jpn 1992; 34:617630.
  • 14
    Mizuno D, Ide-Kurihara M, Ichinomiya T, Kubo I, Kido H. Modified pulmonary surfactant is a potent adjuvant that stimulates the mucosal IgA production in response to the influenza virus antigen. J Immunol 2006; 176:11221130.
  • 15
    Nishino M, Mizuno D, Kimoto T et al. Influenza vaccine with Surfacten, a modified pulmonary surfactant, induces systemic and mucosal immune responses without side effects in minipigs. Vaccine 2009; 27:56205627.
  • 16
    Wright JR, Clements JA. Metabolism and turnover of lung surfactant. Am Rev Respir Dis 1987; 136:426444.
  • 17
    Baritussio A, Pettenazzo A, Benevento M, Alberti A, Gamba P. Surfactant protein C is recycled from the alveoli to the lamellar bodies. Am J Physiol 1992; 263:607611.
  • 18
    Takahashi E, Kataoka K, Fujii K et al. Attenuation of inducible respiratory immune responses by oseltamivir treatment in mice infected with influenza A virus. Microbes Infect 2010; 12:778783.
  • 19
    Asanuma H, Inaba Y, Aizawa C, Kurata T, Tamura S. Characterization of mouse nasal lymphocytes isolated by enzymatic extraction with collagenase. J Immunol Methods 1995; 187:4151.
  • 20
    Ichinohe T, Watanabe I, Ito A et al. Synthetic double-strand RNA poly(I :C) combined with mucosal vaccine protects against influenza virus infection. J Virol 2005; 79:29102919.
  • 21
    Asahi-Ozaki Y, Itamura S, Ichinohe T et al. Intranasal administration of adjuvant-combined recombinant influenza virus HA vaccine protects mice from the lethal H5N1 virus infection. Microbes Infect 2006; 8:27062714.
  • 22
    Tamura S, Shoji Y, Hasiguchi K, Aizawa C, Kurata T. Effects of cholera toxin adjuvant on IgE antibody response to orally or nasally administered ovalbumin. Vaccine 1994; 12:12381240.
  • 23
    Trumpfheller C, Caskey M, Nchinda G et al. The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine. Proc Natl Acad Sci USA 2008; 105:25742579.
  • 24
    Tantilipikorn P, Auewarakul P. Airway allergy and viral infection. Asian Pac J Allergy Immunol 2011; 29:113119.